Prostate Cancer Survival Unhurt by Intermittent Androgen Suppression - OncologySTAT

Prostate Cancer Survival Unhurt by Intermittent Androgen Suppression - OncologySTAT

...Continuous, lifelong androgen deprivation using an LHRH analogue has been the standard of care for men with PSA failure after radical prostate radiotherapy for the past 20 years. PR7 is a large, well-conducted phase III trial that compares this approach with intermittent therapy, using the LHRH analogue for 8 months at a time and then withholding further therapy until the PSA rises above 10 ng/mL. The trial provides good quality evidence that intermittent therapy is as effective as continuous treatment, and that in using the intermittent approach, patients will spend the majority of time off treatment. Given that intermittent therapy will be considerably cheaper than continuous treatment, and less morbid, it should be regarded as the new standard of care for men with PSA failure after radiotherapy......